More NO-no more ROS: Combined selective mineralocorticoid receptor blockade and angiotensin-converting enzyme inhibition for vascular protection

Hypertension

Volumn 51, Issue 3, 2008, Pages 624-625

  Bauersachs, Johann ^a,b   Fraccarollo, Daniela ^a  

^a UNIVERSITY OF WÜRZBURG   (Germany)

^b UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE; ANGIOTENSIN II; ENALAPRIL; EPLERENONE; REACTIVE OXYGEN METABOLITE;

ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CARDIOVASCULAR SYSTEM; CORONARY ARTERY DISEASE; ENDOTHELIAL DYSFUNCTION; ENZYME INHIBITION; HEART FAILURE; HUMAN; NONHUMAN; NOTE; PRIORITY JOURNAL;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; ATHEROSCLEROSIS; HYPERLIPIDEMIAS; NITRIC OXIDE; PEPTIDYL-DIPEPTIDASE A; RABBITS; REACTIVE OXYGEN SPECIES; RECEPTORS, MINERALOCORTICOID;

EID: 39749083959     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.107.106625     Document Type: Note

References (12)

1. Al-Mallah MH, Tleyjeh IM, Abdel-Latif AA, Weaver WD. Angiotensinconverting enzyme inhibitors in coronary artery disease and preserved left ventricular systolic function: a systematic review and meta-analysis of randomized controlled trials. J Am Coll Cardiol. 2006;47:1576-1583.
2. Milliez P, Girerd X, Plouin PF, Blacher J, Safar ME, Mourad JJ. Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism. J Am Coll Cardiol. 2005;45:1243-1248.
3. Schiffrin EL. Effects of aldosterone on the vasculature. Hypertension. 2006;47:312-3188.
4. Nagata D, Takahashi M, Sawai K, Tagami T, Usui T, Shimatsu A, Hirata Y, Naruse M. Molecular mechanism of the inhibitory effect of aldosterone on endothelial NO synthase activity. Hypertension. 2006;48:165-171.
5. Jaffe IZ, Mendelsohn ME. Angiotensin II and aldosterone regulate gene transcription via functional mineralocortocoid receptors in human coronary artery smooth muscle cells. Circ Res. 2005;96:643-650.
6. Mazak I, Fiebeler A, Muller DN, Park JK, Shagdarsuren E, Lindschau C, Dechend R, Viedt C, Pilz B, Haller H, Luft FC. Aldosterone potentiates angiotensin II-induced signaling in vascular smooth muscle cells. Circulation. 2004;109:2792-2800.
7. Funder JW. Mineralocorticoid receptors and cardiovascular damage: it's not just aldosterone. Hypertension. 2006;47:634-635.
8. Bauersachs J, Heck M, Fraccarollo D, Hildemann S, Ertl G, Wehling M, Christ M. Addition of spironolactone to ACE inhibition in heart failure improves endothelial vasomotor dysfunction: role of vascular superoxide anion formation and endothelial NO synthase expression. J Am Coll Cardiol. 2002;39:351-358.
9. Takai S, Jin D, Muramatsu M, Kirimura K, Sakonjo H, Miyazaki M. Eplerenone inhibits atherosclerosis in nonhuman primates. Hypertension. 2005;46:1135-1139.
10. Imanishi T, Ikejima H, Tsujioka H, Kuroi A, Kobayashi K, Muragaki Y, Mochizuki S, Goto M, Yoshida K, Akasaka T. Addition of eplerenone to an angiotensin-converting enzyme inhibitor effectively improves nitric oxide bioavailability. Hypertension. 2008;51:734-741.
11. Bachetti T, Comini L, Pasini E, Cargnoni A, Curello S, Ferrari R. Ace-inhibition with quinapril modulates the nitric oxide pathway in normotensive rats. J Mol Cell Cardiol. 2001;33:395-403.
12. Sartorio CL, Fraccarollo D, Galuppo P, Leutke M, Ertl G, Stefanon I, Bauersachs J. Mineralocorticoid receptor blockade improves vasomotor dysfunction and vascular oxidative stress early after myocardial infarction. Hypertension. 2007;50:919-925.